LASHANDRA GILMORE: Open Payments
NPI 1285336966 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$854 in 47 payments from 12 companies in 2025. Trend: 2023 $197 · 2024 $1,142 · 2025 $854
Food & beverage: $777Education: $77
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 20 | $322 |
| ABBVIE INC. | 4 | $91 |
| Lilly USA, LLC | 4 | $74 |
| Madrigal Pharmaceuticals | 3 | $68 |
| Gilead Sciences, Inc. | 4 | $68 |
| Aimmune Therapeutics, Inc. | 3 | $68 |
| Celltrion USA Inc. | 2 | $45 |
| Phathom Pharmaceuticals, Inc. | 3 | $33 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| QOL Medical, LLC | 1 | $24 |
Products named: TREMFYA, OMVOH, REZDIFFRA, CREON, ZENPEP, VEGZELMA, VOQUEZNA, IQIRVO.
Industry payments across TX — which companies pay providers there.
